THE Brain Tumour Charity has announced that it has appointed Alex Lochrane as its new Chief Executive Officer.
Alex joins The Charity following six and a half years as CEO at Hampshire and Isle of Wight Air Ambulance, where, under his leadership, the organisation delivered a ground-breaking clinical transition strategy and significantly increased its income to grow from 700 to 2,000 critical care response missions per year.
Alex has spent the last 15 years in the voluntary sector, leading The Jubilee Sailing Trust and Chiddingstone Castle before joining Hampshire and Isle of Wight Air Ambulance in 2014.
Prior to moving to the charity sector, Alex had a successful first career as a Royal Navy Officer, rising to the rank of Commander, including sea-going command and combat operational tours (HMS Monmouth, HMS Somerset and HMS Vanguard), as well as shore-based instructional and overseas appointments.
Alex has a post-graduate Diploma in Defence Management from the French Senior Military Staff College in Paris, as well as an Advanced French Language Diploma from the French Ministry of Education. He is also an alumnus of the Kings Fund Top Manager Leadership Programme and the Windsor Leadership Trust.
Alex Lochrane said:
“It is an enormous privilege to be offered this role and I am both humbled and inspired at the prospect of leading this amazing team and helping to guide the charity as it writes the next chapter in its ground-breaking story.
“The Charity has become a bright beacon drawing others to join and collaborate, as well as a lightning rod to channel the voices and powerful lived experiences of friends and families affected by brain tumours into achieving our two unashamedly ambitious goals of doubling survival rates and halving the harm caused by brain tumours; I can’t wait to get started!”
Alex will join The Brain Tumour Charity on Monday 24th January 2022, coming in at a critical time for the organisation as it develops its new five-year organisational strategy, due to be launched at the end of 2022.
Alex takes over the role from Dr David Jenkinson, the organisation’s Chief Scientific Officer, who has led The Charity as Interim CEO since March 2021.
Jack Morris CBE, Chair of Trustees at The Brain Tumour Charity, said:
“We are absolutely delighted to welcome Alex as our new CEO.
“Alex is a seasoned, ambitious and thoughtful leader, with the vision and passion to take The Charity’s impact for friends and families affected by brain tumours to the next level, by extending our reach in both funding world-class research and delivering vital support.
“With a wealth of leadership experience across two distinguished careers both inside and outside the charity sector, we felt he’s the perfect fit to lead our talented team towards our aims to double survival and halve the harm that brain tumours cause.
“I’d also like to say a huge thank you to David Jenkinson for his outstanding contribution in leading The Charity as Interim CEO over the past nine months, ensuring we’re in such a strong position to continue growing our work in 2022 and help accelerate progress for anyone affected by a brain tumour.”
The Brain Tumour Charity, which is the largest dedicated funder of brain tumour research globally, recently launched a new five-year research strategy ‘Accelerating a Cure’, setting out its priorities to create new knowledge, accelerate new treatments and enhance quality of life by aiming to invest another £40m in world-class research by 2027.
Thanks to the generosity of its supporters, volunteers and partners, The Charity was able to raise £8.3 million in 2020/2021, supporting over 27,000 individuals directly through its brain tumour support services while reaching over 1.2 million people worldwide with trusted health and patient information.
The Charity also recently announced that it would be funding a major UK trial of cannabis-based drug Sativex in treating the most aggressive form of brain tumour launching in March 2022, following an outpouring of support for its campaign that had seen over £400,000 donated in just three months.